Follow The Filings

CGEM Cullinan Oncology Inc.

Health Care, filed as CULLINAN ONCOLOGY INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CGEM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CGEM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $1.5M sold by 1 insider under 10b5-1 plans
  1. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $173K 8,000 shares at $21.57 4.8% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  2. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $608K 30,000 shares at $20.26 16% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  3. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $143K 8,000 shares at $17.82 4.7% of stake
    Traded Jul 6 Filed Jul 7
    ↗
  4. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $117K 8,000 shares at $14.62 4.6% of stake
    Traded May 5 Filed May 6
    ↗
  5. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $125K 8,000 shares at $15.68 4.5% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  6. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $25K 1,780 shares at $14.14 1% of stake
    Traded Feb 25 Filed Feb 26
    ↗
  7. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $25K 1,752 shares at $13.99 1% of stake
    Traded Feb 23 Filed Feb 25
    ↗
  8. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $114K 8,000 shares at $14.30 4.2% of stake
    Traded Feb 20 Filed Feb 23
    ↗
  9. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $49K 4,000 shares at $12.30 3% of stake
    Traded Jan 22 Filed Jan 23
    ↗
  10. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $13K 1,345 shares at $10.01 1% of stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
  11. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $12K 995 shares at $11.90 0.7% of stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  12. Jennifer Michaelson Chief Scientific Officer
    Planned sale
    $49K 4,000 shares at $12.30 2.8% of stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗
  13. Lynx1 Capital Management LP 10% owner, +1 joint filer
    Buy
    $1.4M 165,667 shares at $8.40 +1.9% to stake
    Traded Oct 28, 2025 Filed Oct 30, 2025
    ↗
  14. Lynx1 Capital Management LP 10% owner, +1 joint filer
    Buy
    $2.1M 248,749 shares at $8.46
    Traded Oct 14–17 Filed Oct 21, 2025
    ↗
  15. Lynx1 Capital Management LP 10% owner, +1 joint filer
    Buy
    $9.8M 1,459,641 shares at $6.73
    Traded Oct 8–10 Filed Oct 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 15 sales to cover taxes, 6 option exercises, and 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$153.16M -$167.38M -$219.88M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $480.19M $414.67M $386.76M
Total non-current assets * $3.99M $207.16M $61.62M
Total assets $484.18M $621.82M $448.37M
Total current liabilities $28.14M $30.65M $37.74M
Total non-current liabilities * $2.15M $0.849M $1.9M
Total equity $453.7M $590.33M $408.73M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$134.28M -$145.3M -$175.75M
Cash from investing $35.81M -$136.31M $179.99M
Cash from financing $40.75M $266.19M $1.09M
Net change in cash * -$57.72M -$15.43M $5.33M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.